Home  »  Business   »  Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX): A Gre...

Lexicon Pharmaceuticals Inc. (NASDAQ: LXRX): A Great Stock To Watch

Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) shares, rose in value on Wednesday, 06/22/22, with the stock price up by 12.07% to the previous day’s close as strong demand from buyers drove the stock to $1.95.

Actively observing the price movement in the last trading, the stock closed the session at $1.74, falling within a range of $1.715 and $2.0889. The value of beta (5-year monthly) was 1.53. Referring to stock’s 52-week performance, its high was $6.33, and the low was $1.31. On the whole, LXRX has fluctuated by 10.17% over the past month.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.


With the market capitalization of Lexicon Pharmaceuticals Inc. currently standing at about $275.67 million, investors are eagerly awaiting this quarter’s results, scheduled for Mar 08, 2022 – Mar 14, 2022. As a result, investors might want to see an improvement in the stock’s price before the company announces its earnings report. Analysts are projecting the company’s earnings per share (EPS) to be -$0.15, which is expected to increase to -$0.14 for fiscal year -$0.62 and then to about -$0.54 by fiscal year 2023. Data indicates that the EPS growth is expected to be -3.30% in 2023, while the next year’s EPS growth is forecast to be 12.90%.

Wall Street analysts also predicted that in 2023, the company’s y-o-y revenues would reach $170k, representing a decrease of -43.00% from the revenues reported in the last year’s results.

Revisions could be a useful indicator to get insight on short-term price movement; so for the company, there were 1 upward and no downward review(s) in last seven days. We see that LXRX’s technical picture suggests that short-term indicators denote the stock is a 50% Sell on average. However, medium term indicators have put the stock in the category of 50% Sell while long term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the PEG ratio is about 0, with the price of LXRX currently trading nearly 19.38% and 6.50% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 61.11, while the 7-day volatility ratio is showing 12.85% which for the 30-day chart, stands at 8.68%. Furthermore, Lexicon Pharmaceuticals Inc. (LXRX)’s beta value is 1.57, and its average true range (ATR) is 0.15. The company’s stock has been forecasted to trade at an average price of $11.50 over the course of the next 52 weeks, with a low of $5.00 and a high of $18.00. Based on these price targets, the low is -156.41% off current price, whereas the price has to move -823.08% to reach the yearly target high. Additionally, analysts’ median price of $11.50 is likely to be welcomed by investors because it represents a decrease of -489.74% from the current levels.

A comparison of Lexicon Pharmaceuticals Inc. (LXRX) with its peers suggests the former has fared considerably weaker in the market. LXRX showed an intraday change of 12.07% in last session, and over the past year, it shrunk by -58.33%%. In comparison, Aerie Pharmaceuticals Inc. (AERI) has moved lower at -0.88% on the day and was down -61.72% over the past 12 months. On the other hand, the price of Thermo Fisher Scientific Inc. (TMO) has risen 1.11% on the day. The stock, however, is off 5.49% from where it was a year ago. Additionally, there is a gain of 0.10% for Ligand Pharmaceuticals Incorporated (LGND) in last trading while the stock has seen an overall depriciation of -37.91%% over the past year. Other than that, the overall performance of the S&P 500 during the last trading session shows that it lost -0.13%. Meanwhile, the Dow Jones Industrial Slipped by -0.15%.

Data on historical trading for Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) indicates that the trading volumes over the past 3 months, they’ve averaged 499.34K. According to company’s latest data on outstanding shares, there are 149.15 million shares outstanding.

Nearly 1.30% of Lexicon Pharmaceuticals Inc.’s shares belong to company insiders and institutional investors own 83.80% of the company’s shares. The stock has fallen by -50.51% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the LXRX stock heading into the next quarter.

Leave a Comment

Your email address will not be published.

Related Videos

Related Posts